nalysts at First Albany reiterate their "buy" rating on United Therapeutics
Corp (UTHR.NAS), while raising their estimates for the company. The target price
has been raised from $77 to $85. In a research note published this morning,
the analysts mention that the company has reported its 3Q:05 EPS significantly
ahead of and SG&A expenses lower than the estimates. United Therapeutics'
Remodulin sales during the quarter were substantially ahead of the estimates,
the analysts say.